Selux Diagnostics Receives Additional $14.6 Million In Barda Funding After Successfully Completing First Clinical Trial

Jun 08, 2021•about 4 years ago

Amount Raised

$14.6 Million

Boston

Description

Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that it has been awarded an additional $14.6 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

Company Information

Company

The Selux Next Generation Phenotyping Platform

Location

Boston, Massachusetts, United States

About

The proprietary Selux technology uniquely provides targeted therapy results days faster than the current standard of care providing actionable information to inform patient treatment for all Infectious Diseases. Selux's NGP platform provides unprecedented speed-to-results and breadth of menu while meeting the accuracy, throughput, and cost effectiveness requirements of clinical microbiology laboratories and integrated healthcare systems. Caution - The Selux platform is an investigational device, limited by federal law to investigational use

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Selux Diagnostics Receives Additional $14.6 Million In Barda Funding After Successfully Completing First Clinical Trial

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information